Cargando…
The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment
Spinal muscular atrophy (SMA) is currently classified into five different subtypes, from the most severe (type 0) to the mildest (type 4) depending on age at onset, best motor function achieved, and copy number of the SMN2 gene. The two recent approved treatments for SMA patients revolutionized thei...
Autores principales: | Smeriglio, Piera, Langard, Paul, Querin, Giorgia, Biferi, Maria Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564782/ https://www.ncbi.nlm.nih.gov/pubmed/32751151 http://dx.doi.org/10.3390/jpm10030075 |
Ejemplares similares
-
Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials
por: Querin, Giorgia, et al.
Publicado: (2022) -
Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
por: Giorgia, Querin, et al.
Publicado: (2023) -
Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy
por: Cappella, Marisa, et al.
Publicado: (2021) -
AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice
por: Besse, Aurore, et al.
Publicado: (2020) -
Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!
por: Bartlett, Amy, et al.
Publicado: (2018)